Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jan 28, 2005; 11(4): 580-583
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.580
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.580
Table 1 Demographics of patients.
| Parameters | Non-responders (n = 27) |
| Age (yr) | 45.2 |
| Gender-male (%) | 14 (50%) |
| Pretreatment HCV RNA (copies/mL) | 2195150±1575560 |
| Pretreatment ALT (IU/mL) | 142 |
| HCV genotype 1b (%) | 28 (100) |
Table 2 Histological activity index (HAI) and fibrosis stage in all patients.
| HAI Score | n (%) | Stage | n (%) |
| Minimal | 2 (7.1) | 0 | 2 (10.7) |
| Mild | 7 (25) | 1 | 7 (42.9) |
| Moderate | 11 (39.3) | 2 | 11 (10.7) |
| Severe | 7 (25) | 3 | 7 (28.6) |
- Citation: Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, Zengin N, Altiparmak E. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005; 11(4): 580-583
- URL: https://www.wjgnet.com/1007-9327/full/v11/i4/580.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i4.580